Immunotherapy for treating SARS-CoV-2 and liver tumors
Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)
Fondazione IRCCS Policlinico San Matteo di Pavia · NCT06914635
This study is testing new immune treatments to see if they can help fight both COVID-19 and liver tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia (other) |
| Drugs / interventions | atezolizumab, bevacizumab, lenvatinib, cabozantinib |
| Locations | 1 site (Pavia, Pavia) |
| Trial ID | NCT06914635 on ClinicalTrials.gov |
What this trial studies
This project explores two research lines: the first focuses on generating and characterizing human monoclonal antibodies against SARS-CoV-2 through in vitro functional tests. The second line evaluates the immune response efficacy mediated by antibodies targeting specific tumor molecules in liver tumors. The study aims to enhance understanding of immunotherapy's role in combating infectious and tumoral diseases. It is observational in nature, allowing for the collection of data without direct intervention.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with primary liver tumors or those interested in SARS-CoV-2 antibody research.
Not a fit: Patients with active malignancies, autoimmune diseases, or those on specific immunosuppressive therapies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved immunotherapy strategies for patients with SARS-CoV-2 and liver tumors.
How similar studies have performed: Other studies have shown promise in using monoclonal antibodies for similar conditions, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Line 1: - Age \>18 at time of signing informed consent form * Signed informed consent form Line 2: - Primery liver tumor * Age \>18 at time of signing informed consent form * Signed informed consent form Exclusion Criteria: Line 1: - Active or history of neoplastic malignancy * Active autoimmune disease ongoing treatment with immunosuppressive therapy * Evidence of positive HIV, HCV, HBV test * Diabetes * Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months * Chronic autoimmune or inflammatory diseases * Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF therapies * Other extrahepatic neoplasms occurring or in the last 3 years except for tumors resected with curative intent and without evidence of relapse for \>3 years prior to signing informed consent and considered low risk of relapse * HIV infection * Failure to sign informed consent form
Where this trial is running
Pavia, Pavia
- Fondazione IRCCS Policlinico San Matteo di Pavia — Pavia, Pavia, Italy (RECRUITING)
Study contacts
- Study coordinator: Mario Mondelli, MD
- Email: m.mondelli@smatteo.pv.it
- Phone: +390382502639
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: SARS CoV-2, Liver Tumours